Met Life Investment Management, LLC Fulcrum Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

$18.1 Billion
Q1 2025

A detailed history of Met Life Investment Management, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 17,535 shares of FULC stock, worth $110,470. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,535

Previous 40,107 56.28%

Holding current value

$110,470

Previous $188,000 73.4%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$2.88 - $5.08 $65,007 - $114,665	-22,572 Reduced 56.28%	17,535 $50,000
Q4 2024 Feb 13, 2025	BUY	$2.97 - $4.84 $70,662 - $115,153	23,792 Added 145.83%	40,107 $188,000
Q3 2024 Nov 13, 2024	BUY	$3.18 - $9.74 $1,326 - $4,061	417 Added 2.62%	16,315 $58,000
Q2 2024 Aug 13, 2024	BUY	$5.98 - $9.31 $95,070 - $148,010	15,898 New	15,898 $98,000
Q1 2023 May 09, 2024	BUY	$2.83 - $13.99 $78,359 - $387,369	27,689 New	27,689 $78.9 Million
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $24,901 - $123,098	8,799 Added 46.58%	27,689 $78,000
Q4 2022 Jun 14, 2023	SELL	$5.01 - $8.35 $44,082 - $73,471	-8,799 Reduced 31.78%	18,890 $137,000
Q3 2022 May 10, 2024	BUY	$4.92 - $9.1 $19,133 - $35,389	3,889 Added 25.92%	18,890 $150,000
Q3 2022 Jun 14, 2023	SELL	$4.92 - $9.1 $43,291 - $80,070	-8,799 Reduced 31.78%	18,890 $150,000
Q3 2022 Mar 22, 2023	BUY	$4.92 - $9.1 $19,133 - $35,389	3,889 Added 25.92%	18,890 $150,000
Q3 2022 Nov 14, 2022	BUY	$4.92 - $9.1 $92,938 - $171,899	18,890 New	18,890 $153,000
Q2 2022 Aug 11, 2022	SELL	$4.2 - $24.0 $63,004 - $360,024	-15,001 Closed	0 $0
Q1 2022 May 10, 2024	BUY	$9.96 - $23.65 $149,409 - $354,773	15,001 New	15,001 $354,000
Q1 2022 Jun 20, 2023	SELL	$9.96 - $23.65 $126,372 - $300,071	-12,688 Reduced 45.82%	15,001 $354,000
Q1 2022 Mar 22, 2023	BUY	$9.96 - $23.65 $54,242 - $128,797	5,446 Added 57.0%	15,001 $354,000
Q1 2022 May 12, 2022	BUY	$9.96 - $23.65 $54,242 - $128,797	5,446 Added 57.0%	15,001 $355,000
Q4 2021 Jun 21, 2023	SELL	$14.0 - $28.44 $253,876 - $515,730	-18,134 Reduced 65.49%	9,555 $169,000
Q3 2021 May 17, 2024	BUY	$7.28 - $30.97 $69,560 - $295,918	9,555 New	9,555 $269,000
Q3 2021 Jun 21, 2023	SELL	$7.28 - $30.97 $132,015 - $561,609	-18,134 Reduced 65.49%	9,555 $269,000
Q3 2021 Mar 22, 2023	BUY	$7.28 - $30.97 $23,936 - $101,829	3,288 Added 52.47%	9,555 $269,000
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $69,560 - $295,918	9,555 New	9,555 $270,000
Q3 2020 Nov 13, 2020	SELL	$7.22 - $20.7 $45,247 - $129,726	-6,267 Closed	0 $0
Q2 2020 May 24, 2024	BUY	$9.11 - $22.06 $57,092 - $138,250	6,267 New	6,267 $115 Million
Q2 2020 Jun 26, 2023	SELL	$9.11 - $22.06 $195,154 - $472,569	-21,422 Reduced 77.37%	6,267 $114,000
Q2 2020 Mar 22, 2023	SELL	$9.11 - $22.06 $114,995 - $278,463	-12,623 Reduced 66.82%	6,267 $114,000
Q2 2020 Aug 14, 2020	BUY	$9.11 - $22.06 $57,092 - $138,250	6,267 New	6,267 $115,000

Others Institutions Holding FULC

# of Institutions

121

Shares Held

51.9M

Call Options Held

48.9K

Put Options Held

13.8K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $328M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Fulcrum Therapeutics, Inc. Transaction History